Description
Tratamiento de la enfermedad de von Willebrand tipo I
un modulador selectivo del receptor de esfingosina-1-fosfato (S1P)
PRINCIPIO ACTIVO: ACIDO ACETLSALISILICO
bajo indicación médica
00 S/G VITAMINA B6 46
PLENACOR LP 50/20MG CAP C10 ASPEN LABS SA DE CV Tratamiento de la enfermedad dePRINCIPIO ACTIVO: ATENOLOL NIFEDIPINA DOSIS: 50 20 MG FORMA FARMACUTICA: 20 TABLETAS PRESENTACIN: 1 CAJA
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
